drugset
Drugs / DTaP-IPV-HB-PRP~T
last change Mar 2016 re-read 9 days ago

DTaP-IPV-HB-PRP~T

also known as DTaP-IPV-Hep B-PRP-T · Hexaxim

Vaccine

Developed for
diphtheria · hepatitis B virus infection · pertussis · poliomyelitis · haemophilus infectious disease · tetanus
Investigated by
Sanofi Pasteur, a Sanofi Company

Trials 7

today NCT02610348 · not/applicable NCT00619502 · Ph 3 NCT00401531 · Ph 3 NCT00362336 · Ph 3 NCT00313911 · Ph 3 NCT00315055 · Ph 3 NCT00831311 · Ph 2
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial · 1 met primary
Phase 2 NCT00831311 Oct 2004 → Nov 2005 diphtheria, haemophilus infectious disease, pertussis, poliomyelitis +1 Sanofi Pasteur, a Sanofi Company Completed Met primary
Phase 35 trials · 2 met primary
Phase 3 NCT00619502 Dec 2007 → Jul 2008 diphtheria, hepatitis B virus infection, pertussis, poliomyelitis Sanofi Pasteur, a Sanofi Company Completed No outcome recorded
Phase 3 NCT00401531 Oct 2006 → Nov 2007 diphtheria, haemophilus infectious disease, hepatitis B virus infection, pertussis +1 Sanofi Pasteur, a Sanofi Company Completed Met primary
Phase 3 NCT00362336 Aug 2006 → May 2008 diphtheria, haemophilus infectious disease, hepatitis B virus infection, pertussis +1 Sanofi Pasteur, a Sanofi Company Completed Met primary
Phase 3 NCT00313911 Jul 2006 → Jan 2008 diphtheria, haemophilus infectious disease, hepatitis B virus infection, pertussis +1 Sanofi Pasteur, a Sanofi Company Completed No outcome recorded
Phase 3 NCT00315055 Jul 2006 → Jul 2007 diphtheria, hepatitis B virus infection, pertussis, poliomyelitis Sanofi Pasteur, a Sanofi Company Completed No outcome recorded
Phase not applicable1 trial
— NCT02610348 Nov → Dec 2015 hepatitis B virus infection Sanofi Pasteur, a Sanofi Company Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 11 sources stand behind the page.

FieldValueCited text
Known as DTaP-IPV-HB-PRP~T ClinicalTrials.gov intervention name — accepted as the source's own label NCT00831311 ↗
6

NCT00313911 ↗

NCT00315055 ↗

NCT00362336 ↗

NCT00619502 ↗

NCT00401531 ↗

NCT02610348 ↗
Known as DTaP-IPV-Hep B-PRP-T “To assess a new, fully-liquid, hexavalent DTaP-IPV-Hep B-PRP-T vaccine (diphtheria toxoid (D), tetanus toxoid (T), acellular pertussis (aP), inactivated poliovirus (IPV),...” PMID 21334243 ↗ Feb 2011
2

“DTaP-IPV-Hep B-PRP-T vaccine (Hexaxim, Sanofi Pasteur)” PMID 21372751 ↗ Jun 2011

“DTaP-IPV-Hep B-PRP-T vaccine (Hexaxim)” PMID 21289531 ↗ Apr 2011
Known as Hexaxim “DTaP-IPV-Hep B-PRP-T vaccine (Hexaxim, Sanofi Pasteur)” PMID 21372751 ↗ Jun 2011
1

“DTaP-IPV-Hep B-PRP-T vaccine (Hexaxim)” PMID 21289531 ↗ Apr 2011
Modality Vaccine “This new, fully liquid acellular pertussis hexavalent vaccine demonstrated less reactogenicity than the licensed comparator whole cell pertussis vaccine” PMID 22531237 ↗ Aug 2012
Route Intramuscular “0.5 mL, Intramuscular (IM)” NCT00315055 ↗